Supplementary Table 1 Reporting Elements Excluded On the Basis of Perceived Lack of Importance
Excluded Reporting Elements Importance Rating Feasibility Rating Disease Background
Description of the Montreal Classification Med: 3.5 DI: 0.22
Med: 3.5 DI: 0.42 Doses of IBD therapy at the time of the procedure Med: 4.5
DI: 0.32
Med: 4.5 DI: 0.32 Duration of 5-ASA therapy at time of procedure (if
applicable)
Med: 3.5 DI: 0.52
Med: 4 DI: 0.0 Duration of IS therapy at time of procedure (if
applicable)
Med: 4 DI: 0.32
Med: 4 DI: 0.0 Duration of biologic therapy at time of procedure (if
applicable)
Med: 4.5 DI: 0.32
Med: 4 DI: 0.0 Description of previously failed therapies Med: 3.5
DI: 0.22
Med: 3 DI: 0.15 Description of previous medication intolerance Med: 2.3
DI: 0.12
Med: 3 DI: 0.22 Time since last dose of biologic (if applicable) Med: 4.0
DI: 0.22
Med: 4 DI: 0.21 Description of time since last endoscopic evaluation Med: 4
DI: 0.42
Med: 5 DI: 0.38 Findings and Interventions
Maximal distance of ileal insertion Med: 6
DI: 2.15
Med: 8 DI: -0.71 Description of pertinent positives/negatives re: stigmata
of perianal CD (fissures, fistulas, skin tags) in UC
Med: 6.4 DI: 2.72
Med: 6.5 DI: -3.08 Non validated general description of UC disease activity Med: 5.5
DI: 1.96
Med: 5 DI: 1.58 Non validated general description of CD disease activity Med: 5.5
DI: 1.96
Med: 5 DI: 1.5
Use of segmental Mayo sub-score Med: 3.3
DI: 0.47
Med: 4 DI: 0.42
Description of ileocecal valve Med: 4.5
DI: 0.32
Med: 7 DI: -2.15 Description of pit pattern of any polypoid lesion Med: 4
DI: 0.42
Med: 3 DI: 0 Elements Specific to a Colonoscopy in the Context of an Ileocolonic Anastomosis
Description of the type of anastomosis (eg. End to end, side to side)
Med: 5 DI: 0.38
Med: 4 DI: 0.63 Elements Specific to a Pouchoscopy
Name and dose of specific IBD/pouch therapy at the time of the pouchoscopy
Med: 5 DI: 0.24
Med: 4.5 DI: 0.66 Duration of specific IBD/pouch therapy at the time of
the pouchoscopy
Med: 5 DI: 0.32
Med: 4.5 DI: 0.32 Description of previously failed therapies Med: 3.5
DI: 0.42
Med: 3.0 DI: 0.30 Description of type of pouch surgery (1 , 2, or 3 stage) Med: 2
DI: 0.11
Mean: 3.0 DI: 0.33 Description of date of pouch surgery Med: 3
DI: 0.12
Med: 3 DI: 0.26
Description of date of takedown of diverting loop ileostomy
Med: 3 DI: 0.16
Med: 3 DI: 0.33 Description of time from dose of last biologic (if
applicable)
Med: 4.5 DI: 0.47
Med: 4 DI: 0.36 Description of time since last endoscopic evaluation Med: 5
DI: 0.32
Med: 4.5 DI: 0.66 Recommendations
Recommendations regarding change in therapy Med: 6 DI: 2.72
Med: 6.5 DI: 2.72
Give time for next appointment Med: 3
DI: 0.36
Med: 3 DI: 0.68
Recommend time for next colonoscopy Med: 5
DI: 0.47
Med: 5.5 DI: 1.44 Description of biopsies of flat mucosa
Description of the approximate number of biopsies obtained overall in the setting of disease activity assessmentA
Med: 5 DI: 0.66
Med: 6 DI: 0.42 Description of method of obtaining biopsies when
indication was dysplasia surveillance (e.g. 4 quadrant biopsies every 10cm)
Med: 5.5 DI: 2.35
Med: 7 DI: -2.95 Med: Median
DI: Disagrement index (see Methods)
AThis endoscopy element was statistically deemed important when the absolute indication was dysplasia surveillance, but it did not meet criteria for inclusion when the indication was disease activity assessment.
5-ASA: 5-aminosalicylates, IS: immunosuppressive, CD: Crohn’s disease